---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-009264"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:29:55.153135+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myomo reports prelim Q4 revenue $4.6-$4.8M (+14-19% YoY), raises $6M in registered direct offering

## Summary
- Preliminary Q4 2023 revenue expected $4.6-$4.8M, up 14-19% YoY; cash $8.7M at Dec 31, 2023.
- Backlog of ~230 patients as of Dec 31, 2023, up ~40% YoY; CMS classified MyoPro as a brace, reimbursed lump sum.
- Raised $6M gross via registered direct offering of 1.58M shares/pre-funded warrants at $3.80, priced at market.
- Proceeds to scale up for Medicare Part B, hire ~50 people; expects cash flow breakeven by Q4 2024.
- CEO targets $100M annual revenue within five years; offering includes insiders and institutional investors.

## SEC filing metadata
- accession: 0001193125-24-009264
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/d573347d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-009264
- JSON: https://secwatch.observer/filing/0001193125-24-009264.json
- Plain text: https://secwatch.observer/filing/0001193125-24-009264.txt

## Key facts
- Earnings Releases
  MYOMO, INC. reported the fourth quarter of 2023 results: revenue in the range of $4.6 million to $4.8 million.
  - Period: the fourth quarter of 2023
  - Revenue: in the range of $4.6 million to $4.8 million
  - Result: preliminary results
  source text: Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm
- Material Agreements
  MYOMO, INC. entered into Purchase Agreement with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company valued at gross proceeds of $6 million (effective 2024-01-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company
  - Value: gross proceeds of $6 million
  - Effective: 2024-01-16
  source text: On January 16, 2024, Myomo, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) (i) 1,354,218 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share” and collectively the “Shares”); and (ii) pre-funded warrants in lieu of shares of Common Stock (the “Pre-Funded Warrants”) to purchase 224,730 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000119312524009264/0001193125-24-009264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.